Finance

Beta
Lists
818:FRA
Zylox-Tonbridge Medical Technolgy Co Ltd
€1.98
-1.98%
(-0.040) 1D
Jun 17, 9:55:02 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 818...
Open
€1.98
High
€1.98
Low
€1.98
Mkt. cap
6.23B
Avg. vol.
1.00
Volume
0.00
52-wk high
€2.98
52-wk low
€1.95
No. of employees
925
Open
€1.98
High
€1.98
Low
€1.98
Mkt. cap
6.23B
Avg. vol.
1.00
Volume
0.00
52-wk high
€2.98
52-wk low
€1.95
No. of employees
925
News stories
From sources across the web
About Zylox-Tonbridge Medical Technolgy Co Ltd
CEO-
Employees925
Founded2012
Headquarters-
SectorMedical device
Websitezyloxtb.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
240.98M
240.98M
287.76M
287.76M
Cost of goods sold
69.43M
69.43M
77.86M
77.86M
Cost of revenue
69.43M
69.43M
77.86M
77.86M
Research and development expenses
60.80M
60.80M
62.59M
62.59M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
70.60M
70.60M
87.34M
87.34M
Operating expense
134.47M
134.47M
147.58M
147.58M
Total operating expenses
203.90M
203.90M
225.43M
225.43M
Operating income
37.08M
37.08M
62.33M
62.33M
Other non operating income
10.45M
10.45M
-16.62M
-16.62M
EBT including unusual items
60.60M
60.60M
57.77M
57.77M
EBT excluding unusual items
60.28M
60.28M
58.45M
58.45M
Income tax expense
-
-
-3.82M
-3.82M
Effective tax rate
-
-
-6.60%
-6.60%
Other operating expenses
3.07M
3.07M
-2.35M
-2.35M
Net income
60.60M
60.60M
61.59M
61.59M
Net profit margin
25.15%
25.15%
21.40%
21.40%
Earnings per share
-
-
-
-
Interest and investment income
14.16M
14.16M
15.52M
15.52M
Interest expense
-600.00K
-600.00K
-
-
Net interest expenses
13.56M
13.56M
15.52M
15.52M
Depreciation and amortization charges
-
-
-
-
EBITDA
45.76M
45.76M
70.20M
70.20M
Gain or loss from assets sale
-
-
45.00K
45.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer